Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT04444622 2025-10-20

STIMVAX

Phase 2 Completed

29 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01312857 2025-10-09

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Phase 2 Completed

75 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT05104567 2025-09-24

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Phase 2 Completed

138 enrolled 32 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02978612 2025-09-05

ACE

Phase 2 Completed

170 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05480306 2025-08-03

DeFianCe

Phase 2 Completed

188 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

132 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03584711 2025-06-29

OPTIPRIME

Phase 2 Completed

118 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05513742 2025-06-26

COMPANION-003

Phase 2 Completed

49 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

123 enrolled 21 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Phase 2 Completed

59 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05546476 2025-05-31

PROACC-1

Phase 2 Completed

187 enrolled 24 charts

GastrointestinalThoracic

Anorexia, Cachexia, Carcinoma, Non-Small-Cell Lung, Fatigue, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Weight Loss

NCT02380443 2025-05-16

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

Phase 2 Completed

13 enrolled 8 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06137248 2025-05-06

ROSANNA

Phase 2 Completed

76 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04907539 2025-04-16

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2 Completed

25 enrolled 22 charts

Gastrointestinal

Colorectal Neoplasms

NCT05004350 2025-04-15

NAUTICALCRC

Phase 2 Completed

107 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04072198 2025-03-13

NIVACOR

Phase 2 Completed

73 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05061017 2025-03-07

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Phase 2 Completed

13 enrolled 25 charts

DermatologicGastrointestinal

Melanoma, Colorectal Neoplasms

NCT03396926 2025-02-28

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Phase 2 Completed

44 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT01652196 2025-02-05

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Phase 2 Completed

56 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04895137 2025-01-22

BASKETⅡ

Phase 2 Completed

42 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05593328 2025-01-10

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2 Completed

23 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04513951 2025-01-09

AVETRIC

Phase 2 Completed

62 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03841305 2025-01-03

HYPER-LIV01

Phase 2 Completed

64 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT01539824 2024-11-25

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Phase 2 Completed

12 enrolled 6 charts

Gastrointestinal

Colorectal Neoplasms

NCT03631407 2024-11-21

MK-7690-046

Phase 2 Completed

41 enrolled 20 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02040142 2024-10-24

HIPEC for Peritoneal Carcinomatosis

Phase 2 Completed

51 enrolled 12 charts

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Stomach Neoplasms, Colorectal Neoplasms

NCT03435107 2024-10-15

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Phase 2 Completed

33 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms

NCT03475004 2024-09-19

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Phase 2 Completed

53 enrolled 14 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT06597903 2024-09-19

A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution

Phase 2 Completed

36 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03800602 2024-09-05

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

Phase 2 Completed

29 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT02860546 2024-09-03

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Phase 2 Completed

18 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02705300 2024-08-29

Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

Phase 2 Completed

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02873195 2024-08-23

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

133 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT00378482 2024-08-22

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Phase 2 Completed

37 enrolled 13 charts

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT03274882 2024-07-25

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Phase 2 Completed

26 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00891930 2024-07-17

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Phase 2 Completed

74 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT02384759 2024-07-10

FOLFA

Phase 2 Completed

117 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03144804 2024-06-06

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

Phase 2 Completed

36 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

CAIRE

ARETHUSA

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

18F-FAPI-74 GI

DESTINY-CRC02

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

Window of Opportunity Study in Colorectal Cancer

NAVIGATE

STIMVAX

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

ACE

DeFianCe

SAMCO

OPTIPRIME

COMPANION-003

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

PROACC-1

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

ROSANNA

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

NAUTICALCRC

NIVACOR

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

BASKETⅡ

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

AVETRIC

HYPER-LIV01

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

MK-7690-046

HIPEC for Peritoneal Carcinomatosis

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

FOLFA

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer